Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Nerve Growth Factor Market from 2024 to 2025?

In recent times, the nerve growth factor (NGF) market has experienced significant expansion. The market, which stood at $1.11 billion in 2024, is projected to rise to $1.20 billion in 2025, registering a compound annual growth rate (CAGR) of 8.4%. This upward trend during the historic period is associated with factors such as the rising number of traumatic brain injuries, a higher prevalence of neurodegenerative diseases, an uptick in research and development activities, greater public understanding of nerve regeneration therapies, and an increased number of peripheral neuropathy cases.

What Is the Projected Market Size of the Nerve Growth Factor Market?

A significant expansion is predicted in the nerve growth factor (NGF) market size over the next several years. The market is projected to reach approximately $1.63 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. This expected growth within the forecast period can be attributed to various factors such as the growing demand for biopharmaceuticals, increasing incidence of autoimmune neurological disorders, enhanced focus on neuroinflammation research, increased investments in AI-powered drug discovery and a rising customer demand for NGF-based treatments. Key trends during this forecast period are expected to be improvements in biotechnology, personalised medicine strategies, innovative drug delivery systems, regulatory authorisations and the creation of nerve growth factor (NGF) antibodies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22070&type=smp

Who are the Major Competitors in the Nerve Growth Factor Market Outlook?

Major companies operating in the nerve growth factor market are Pfizer Inc., AstraZeneca Plc, Eli Lilly & Company, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals Inc., Genetech, Dompé farmaceutici S.p.A., Promega Corporation, Akeso Inc, CUSABIO TECHNOLOGY LLC, Staidson Beijing BioPharmaceuticals, Biocare Medical LLC, Beike Biotechnology, Enzo Life Sciences Inc., Genexis Biotech Pvt. Ltd., Mimetogen Pharmaceuticals, Alomone Labs, MimeTech Srl, Herantis Pharma, Prospec-Tany Technogene Ltd., PainCeptor Pharma

What Is Fueling Growth in the Nerve Growth Factor Market?

The nerve growth factor market is set to burgeon due to the escalating occurrence of neurological diseases. These diseases, which implicate the brain, spinal cord, and nerves, stem from structural, electrical or biochemical abnormalities. The escalating occurrence can be attributed to an aging demographic and advancements in diagnostic technology. Such advancements have facilitated the improved detection and reporting of these conditions, resulting in increased recorded incidence rates. Nerve growth factor (NGF) is pivotal in the upkeep, survival, and regeneration of neurons, earmarking it as a critical element in tackling the widespread of neurological diseases by encouraging neural repair and possibly decelerating the progression of the disease. Take for example the prediction made by the Australian Institute of Health and Welfare, a government agency based in Australia, in September 2024. It forecasts that dementia (a kind of neurological disease) cases in Australia will soar from approximately 411,100 in 2023 to 849,300 by 2058. Hence, the escalating occurrence of these neurological diseases is catalyzing the growth of the nerve growth factor market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22070&type=smp

Which Nerve Growth Factor Market Segments Are Growing the Fastest?

The nerve growth factor market covered in this report is segmented –

1) By Type: Alpha-Nerve Growth Factor (NGF), Beta-Nerve Growth Factor (NGF), Gamma-Nerve Growth Factor (NGF), Other Types

2) By Agents: Cenegermin, Other Agents

3) By Indication: Neurodegenerative Disorders, Spinal Cord Injuries, Eye Disorders, Epithelial Diseases, Tissue Healing, Other Indications

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Alpha-Nerve Growth Factor (a-NGF): Natural Alpha-NGF, Recombinant Alpha-NGF, Synthetic Alpha-NGF, Alpha-NGF For Research Applications

2) By Beta-Nerve Growth Factor (ß-NGF): Human Beta-NGF, Animal-Derived Beta-NGF, Recombinant Beta-NGF, Therapeutic Beta-NGF, Research-Grade Beta-NGF

3) By Gamma-Nerve Growth Factor (?-NGF): Natural Gamma-NGF, Recombinant Gamma-NGF, Synthetic Gamma-NGF, Gamma-NGF for Neurodegenerative Research

4) Other Types: Hybrid NGF Molecules, NGF Mimetics, NGF Gene Therapy-Based Products, NGF-Infused Biomaterials

Which Industry Trends Are Shaping the Future of the Nerve Growth Factor Market?

Prominent firms in the nerve growth factor market are concentrating on the creation of sophisticated products like nerve growth factor (NGF) monoclonal antibodies that inhibit NGF, with the aim of providing effective analgesia. An NGF monoclonal antibody is a biologic medication that targets and mitigates nerve growth factor (NGF) to prevent receptor communication, thereby diminishing pain and nerve inflammation. This aids in the management of pain signals and the survival of nerve cells. As an example, Akeso, Inc., a biopharmaceutical corporation based in China, launched AK115 in February 2022. This humanized IgG1 monoclonal antibody has been approved by the National Medical Products Administration in China to begin clinical trials for various pain treatments, including that related to cancer. AK115 is devised to hinder NGF’s interaction with receptors, intending to lessen pain while ensuring long-term safety, non-dependency, and enhanced efficacy particularly for cancer patients who are resistant to opioids. This futuristic analgesic’s goal is to deliver sustained, non-dependency inducing pain relief, specifically to opioid-resistant cancer patients, augmenting their quality of life.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/nerve-growth-factor-global-market-report

Which Countries Are Leading the Nerve Growth Factor Market?

Asia-Pacific was the largest region in the nerve growth factor market in 2024. The regions covered in the nerve growth factor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22070

This Report Delivers Insight On:

1. How big is the nerve growth factor market, and how is it changing globally?

2. Who are the major companies in the nerve growth factor market, and how are they performing?

3. What are the key opportunities and risks in the nerve growth factor market right now?

4. Which products or customer segments are growing the most in the nerve growth factor market?

5. What factors are helping or slowing down the growth of the nerve growth factor market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.